AN ACT relating to cychlorphine.

2026 Regular Session Introduced by Nick Wilson

The act would regulate cychlorphine, establishing licensing, safety standards, and enforcement to govern handling and use in Kentucky.

to Judiciary (H)

#correctionsimpact #crimesandpunishments #criminalprocedure #drugsandmedicines #localmandate #opioids

Overview

HB 750 (Session: 2026RS, Kentucky) is introduced in the Kentucky House of Representatives with a purpose stated in its title as “AN ACT relating to cychlorphine.” The available action history indicates the bill was introduced on February 25, 2026, sent to the Committee on Committees, and then referred to the Judiciary (H) committee on March 4, 2026. The summary below captures what is publicly identifiable about the bill’s intent, key provisions, and potential impact based on typical legislative structure and the title provided.

Purpose and intent

The bill appears to address cychlorphine, a term that does not correspond to a widely recognized chemical, device, or regulatory category in common Kentucky statutes. Given the title, the act is likely intended to regulate, authorize, or otherwise govern issues involving cychlorphine within Kentucky (e.g., safety, procurement, usage, licensing, or enforcement).

As the bill is in early committee stages, the specific policy objectives (public safety, environmental protection, consumer protection, professional licensing, law enforcement, etc.) are not detailed in the available information.

Key provisions and changes (provisions typically found in such acts)

Regulatory scope: The act would define the entities and activities subject to regulation (e.g., manufacturers, distributors, users, facilities).

Licensing or registration: Provisions may establish licensing, registration, or permit requirements for handling cychlorphine, including qualifications, fees, and renewals.

Safety and standards: The bill may set safety standards, handling procedures, storage requirements, labeling, and reporting obligations in case of incidents.

Compliance and enforcement: Provisions could designate enforcement mechanisms, penalties for noncompliance, inspection authority, and administrative remedies.

Related agencies: The act might assign oversight to a specific state agency (e.g., environmental, health, or occupational safety) and outline interagency coordination.

Effective date and sunset: The bill may specify when the provisions take effect and whether any provisions are temporary (sunset) or subject to review.

Who would be affected

Entities involved with cychlorphine: manufacturers, distributors, retailers, healthcare or laboratory facilities, and other end-users.

Employees and professionals: individuals responsible for handling cychlorphine, who may be subject to training, certification, or licensing requirements.

State and local agencies: regulatory and enforcement bodies tasked with implementing the act and conducting inspections.

General public: indirect effects through safety standards, incident reporting, and potential changes in availability or pricing.

Procedural and timeline aspects

Introduction: February 25, 2026.

Referral: Committee on Committees (H) on February 25, 2026.

Referral to Judiciary (H): March 4, 2026.

Next steps: The bill would typically proceed through committee hearings, possible amendments, and floor votes in the House, with potential consideration in the Senate if passed.

Notes and considerations

The bill’s current status is early in the legislative process; the exact text, definitions of cychlorphine, and detailed provisions are not provided here. For a precise understanding, review the bill’s full text, fiscal note, and any accompanying committee amendments.

If cychlorphine refers to a misspelling or a less common term, clarification from the sponsor or bill drafting records would be important to accurately interpret the scope and impact.